Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP 01: Camrelizumab and Apatinib in Recurrent Resistant GTN
NCT04047017Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gestational trophoblastic neoplasia (GTN), sponsored by Peking Union Medical College Hospital. Started Aug 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT04047017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047017.